Beam Therapeutics (BEAM) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Vision and technology

• Aims to deliver lifelong cures for serious diseases using base editing, a precise gene editing technology with platform potential for rapid retargeting to multiple diseases.

• Base editing enables single-letter changes in DNA without double-stranded breaks, offering more versatility and safety compared to traditional nucleases.

• Holds a dominant IP position in base editing, with clinical proof of concept and robust manufacturing and delivery capabilities, including ex vivo and in vivo (LNP) approaches.

• Financially strong with $850 million in cash, supporting operations and commercial readiness into 2027.

Clinical programs and pipeline progress

• BEAM-101 for sickle cell disease shows promising early results: rapid engraftment, efficient cell collection, and induction of protective fetal hemoglobin, with no serious adverse events related to the therapy.

• Over 40 patients enrolled in BEACON trial, with adolescent cohort open and BLA filing anticipated as the 30th patient is dosed mid-year.

• BEAM-302 for Alpha-1 antitrypsin deficiency is open in four markets, with first clinical data expected in the first half of the year across multiple cohorts.

• BEAM-301 for glycogen storage disease 1A is in phase I/II, with first patient dosing expected early 2025; animal studies show resolution of hepatomegaly and dyslipidemia.

• ESCAPE platform (BEAM-103/104) aims to eliminate chemotherapy using antibody conditioning, with promising NHP data and phase I study planned by year-end.

Market opportunity and strategy

• Sickle cell market segmented into three waves: severe patients (wave one), broader population without chemotherapy (wave two), and future in vivo delivery (wave three).

• Wave one market estimated at $1.5 billion annually in the U.S., with growth expected as operational and reimbursement challenges are addressed.

• Supply of manufacturing slots seen as the main constraint for market growth, with rapid engraftment reducing hospital bed needs.

• Collaborations with Apellis and Pfizer, including a late preclinical program targeting FcRn for autoimmune disorders.